Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links

U.S. Department of Health and Human Services

FDA, U.S. Food and Drug Administration

U.S. Food & Drug Administration

A to Z Index
Follow FDA
FDA Voice Blog

Enter Search terms

Most Popular Searches

Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products

Drugs

Home
Drugs
Guidance, Compliance & Regulatory Information

Section Contents Menu

Guidance, Compliance & Regulatory Information

CDER FOIA Electronic Reading Room
Good Review Practices (GRPs)

Laws, Acts, and Rules
Guidances (Drugs)
Enforcement Activities by FDA
Drug Registration and Listing
Imports and Exports Compliance
Surveillance
Postmarket Requirements and Commitments
Pharmacy Compounding

-

Phase IV Protocol of Glucophage (NDA 20-357)

-

-

Page Last Updated: 04/30/2009
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

Accessibility
Contact FDA
Careers
FDA Basics
FOIA
No Fear Act
Site Map
Transparency
Website Policies

FDA

U.S. Food and Drug Administration

10903 New Hampshire Avenue
Silver Spring, MD 20993
Ph. 1-888-INFO-FDA (1-888-463-6332)
Email FDA

For Government
For Press

Combination Products
Advisory Committees
Science & Research
Regulatory Information
Safety
Emergency Preparedness
International Programs
News & Events
Training and Continuing Education
Inspections/Compliance
State & Local Officials
Consumers
Industry
Health Professionals
FDA Archive

U.S. Department of Health & Human Services

Links on this page: